Mammalian Target of Rapamycin (mTOR) Activity Dependent Phospho-Protein Expression in Childhood Acute Lymphoblastic Leukemia (ALL)

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Nemes, Karolina ^a,b   Sebestyén, Anna ^b,c   Márk, Ágnes ^b   Hajdu, Melinda ^b   Kenessey, István ^b   Sticz, Tamás ^b   Nagy, Eszter ^d   Barna, Gábor ^b   Váradi, Zsófia ^a,b   Kovács, Gábor ^a   Kopper, László ^b   Csóka, Monika ^a,b,c,d  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; METHYLPREDNISOLONE; PHOSPHOPROTEIN; PROTEIN S6; RAPAMYCIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LEUKEMIA RELAPSE; LYMPHOBLAST; MALE; OPTICAL DENSITY; PATIENT IDENTIFICATION; PATIENT SELECTION; PRESCHOOL CHILD; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TREATMENT FAILURE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DRUG SYNERGISM; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; MULTIVARIATE ANALYSIS; PHOSPHOPROTEINS; PHOSPHORYLATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN PROCESSING, POST-TRANSLATIONAL; RIBOSOMAL PROTEIN S6 KINASES; ROC CURVE; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EUKARYOTA; MAMMALIA;

EID: 84875692417     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059335     Document Type: Article

References (47)

1. Torok S, Borgulya G, Lobmayer P, Jakab Z, Schuler D, et al. (2005) Childhood leukaemia incidence in Hungary, 1973-2002. Interpolation model for analysing the possible effects of the Chernobyl accident. Eur J Epidemiol 20: 899-906.
2. Kaatsch P, (2010) Epidemiology of childhood cancer. Cancer Treat Rev 36: 277-285.
3. Pui CH, Evans WE, (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354: 166-178.
4. Pui CH, Cheng C, Leung W, Rai SN, Rivera GK, et al. (2003) Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 349: 640-649.
5. Brown P, Hunger SP, Smith FO, Carroll WL, Reaman GH, (2009) Novel targeted drug therapies for the treatment of childhood acute leukemia. Expert Rev Hematol 2: 145.
6. Lee-Sherick AB, Linger RM, Gore L, Keating AK, Graham DK, (2010) Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development. Br J Haematol 151: 295-311.
7. Dow LW, Martin P, Moohr J, Greenberg M, Macdougall LG, et al. (1985) Evidence for clonal development of childhood acute lymphoblastic leukemia. Blood 66: 902-907.
8. Teachey DT, Obzut DA, Cooperman J, Fang J, Carroll M, et al. (2006) The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107: 1149-1155.
9. Yee KW, Zeng Z, Konopleva M, Verstovsek S, Ravandi F, et al. (2006) Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 12: 5165-5173.
10. Schmelzle T, Hall MN, (2000) TOR, a central controller of cell growth. Cell 103: 253-262.
11. Houghton PJ, Huang S (2003) mTOR as a target for cancer therapy. Tor-Target of Rapamycin. Berlin: Springer-Verlag Berlin. 339-359.
12. Bhaskar PT, Hay N, (2007) The two TORCs and Akt. Dev Cell 12: 487-502.
13. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, et al. (2001) Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes & Development 15: 2852-2864.
14. Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE, (1992) Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 257: 973-977.
15. Akcakanat A, Singh G, Hung MC, Meric-Bernstam F, (2007) Rapamycin regulates the phosphorylation of rictor. Biochem Biophys Res Commun 362: 330-333.
16. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, et al. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168.
17. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, et al. (2009) High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 114: 647-650.
18. Inoki K, Corradetti MN, Guan KL, (2005) Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37: 19-24.
19. Hay N, (2005) The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8: 179-183.
20. Bertrand FE, Spengemen JD, Shelton JG, McCubrey JA, (2005) Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support. Leukemia 19: 98-102.
21. Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, et al. (2004) JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 18: 189-218.
22. Leclerc GM, Leclerc GJ, Fu G, Barredo JC, (2010) AMPK-induced activation of Akt by AICAR is mediated by IGF-1R dependent and independent mechanisms in acute lymphoblastic leukemia. J Mol Signal 5: 15.
23. O'Neil J, Grim J, Strack P, Rao S, Tibbitts D, et al. (2007) FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 204: 1813-1824.
24. Staehler M, Haseke N, Khoder W, Stief CG, (2010) Profile of temsirolimus in the treatment of advanced renal cell carcinoma. Onco Targets Ther 3: 191-196.
25. Hess G, Smith SM, Berkenblit A, Coiffier B, (2009) Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Oncol 36Suppl 3: S37-45.
26. Vignot S, Faivre S, Aguirre D, Raymond E, (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16: 525-537.
27. Muthukkumar S, Ramesh TM, Bondada S, (1995) Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation 60: 264-270.
28. Ringshausen I, Peschel C, Decker T, (2005) Mammalian target of rapamycin (mTOR) inhibition in chronic lymphocytic B-cell leukemia: a new therapeutic option. Leuk Lymphoma 46: 11-19.
29. Avellino R, Romano S, Parasole R, Bisogni R, Lamberti A, et al. (2005) Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood 106: 1400-1406.
30. Brown VI, Fang J, Alcorn K, Barr R, Kim JM, et al. (2003) Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling. Proc Natl Acad Sci U S A 100: 15113-15118.
31. Mihalik R, Uher F, Pocsik EE, Berczi L, Benczur M, et al. (1996) Detection of Drug-induced Apoptosis by Flow Cytometry after Alkaline Extraction of Ethanol Fixed Cells. Pathol Oncol Res 2: 78-83.
32. Gong J, Traganos F, Darzynkiewicz Z, (1994) A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem 218: 314-319.
33. Teachey DT, Grupp SA, Brown VI, (2009) Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 145: 569-580.
34. Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, et al. (2008) Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 799-805.
35. Dekter HE, Romijn FP, Temmink WP, van Pelt J, de Fijter JW, et al. (2010) A spectrophotometric assay for routine measurement of mammalian target of rapamycin activity in cell lysates. Anal Biochem 403: 79-87.
36. Jiang BH, Liu LZ, (2008) Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 11: 63-76.
37. Teachey DT, Sheen C, Hall J, Ryan T, Brown VI, et al. (2008) mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 112: 2020-2023.
38. Pulsipher MA, Wall DA, Grimley M, Goyal RK, Boucher KM, et al. (2009) A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL). Br J Haematol 147: 691-699.
39. Fouladi M, Laningham F, Wu J, O'Shaughnessy MA, Molina K, et al. (2007) Phase I study of everolimus in pediatric patients with refractory solid tumors. J Clin Oncol 25: 4806-4812.
40. Gu L, Zhou C, Liu H, Gao J, Li Q, et al. (2010) Rapamycin sensitizes T-ALL cells to dexamethasone-induced apoptosis. J Exp Clin Cancer Res 29: 150.
41. Crazzolara R, Cisterne A, Thien M, Hewson J, Baraz R, et al. (2009) Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia. Blood 113: 3297-3306.
42. Saunders P, Cisterne A, Weiss J, Bradstock KF, Bendall LJ, (2011) The mammalian target of rapamycin inhibitor RAD001 (everolimus) synergizes with chemotherapeutic agents, ionizing radiation and proteasome inhibitors in pre-B acute lymphocytic leukemia. Haematologica 96: 69-77.
43. Gu L, Gao J, Li Q, Zhu YP, Jia CS, et al. (2008) Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis. Leukemia 22: 2091-2096.
44. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, et al. (2006) Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10: 331-342.
45. Sebestyén A, Sticz TB, Márk Á, Hajdu M, Timár B, et al. (2012) Activity and complexes of mTOR in Diffuse large B cell lymphomas- a tissue microarray study. Mod Pathol 25: 1623-1628.
46. Evangelisti C, Ricci F, Tazzari P, Tabellini G, Battistelli M, et al. (2011) Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia.
47. Janes MR, Limon JJ, So L, Chen J, Lim RJ, et al. (2010) Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16: 205-213.